keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial carcinoma

keyword
https://www.readbyqxmd.com/read/29139108/a-3-untranslated-region-polymorphism-rs2304277-in-the-dna-repair-pathway-gene-ogg1-is-a-novel-risk-modulator-for-urothelial-bladder-carcinoma
#1
Tayyaba Ahmed, Saira Nawaz, Rabia Noreen, Kashif Sardar Bangash, Abdur Rauf, Muhammad Younis, Khursheed Anwar, Muhammad Athar Khawaja, Maleeha Azam, Abid Ali Qureshi, Saeed Akhter, Lambertus A Kiemeney, Raheel Qamar, Syeda Hafiza Benish Ali
Altered DNA repair capacity may affect an individual's susceptibility to cancers due to compromised genomic integrity. This study was designed to elucidate the association of selected polymorphisms in DNA repair genes with urothelial bladder carcinoma (UBC). OGG1 rs1052133 and rs2304277, XRCC1 rs1799782 and rs25487, XRCC3 rs861539, XPC rs2228001, and XPD rs13181 were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 UBC cases and 200 controls. We found association of OGG1 rs2304277 [odds ratio (OR)GG = 3...
November 15, 2017: Annals of Human Genetics
https://www.readbyqxmd.com/read/29139021/perioperative-complications-and-mortality-in-patients-with-urothelial-carcinoma-and-end-stage-renal-disease-undergoing-one-stage-complete-urinary-tract-extirpation
#2
Yun-Ching Huang, Ying-Hsu Chang, Alan W Shindel, Yin-Lun Chang, Jian-Hui Lin, Dong-Ru Ho, Chih-Shou Chen
BACKGROUND: Complete urinary tract extirpation (CUTE) is a complex procedure with substantial risk for perioperative complications. The association between clinical characteristics and the risk of major postoperative complications has not been systematically investigated. OBJECTIVE: The aim of this study was to analyze the incidence and risks for major perioperative complications after CUTE. METHODS: Respective chart review of 81 patients with urothelial carcinoma (UC) who were treated with one-stage CUTE between January 2004 and December 2015...
November 14, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29137333/preoperative-chronic-kidney-disease-predicts-poor-oncological-outcomes-after-radical-nephroureterectomy-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#3
Hirotake Kodama, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Go Anan, Ken Fukushi, Takuma Narita, Toshikazu Tanaka, Yuka Kubota, Hirotaka Horiguchi, Masaki Momota, Koichi Kido, Teppei Matsumoto, Osamu Soma, Itsuto Hamano, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Atsushi Sasaki, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Objective: To evaluate the impact of preoperative chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial carcinoma who underwent radical nephroureterectomy. Methods: A total of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017 were retrospectively examined. Oncological outcomes, including intravesical recurrence-free, visceral recurrence-free, cancer-specific, and overall survival rates (intravesical RFS, visceral RFS, CSS, and OS, respectively) stratified by preoperative CKD status (CKD vs...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136187/a-phase-iii-trial-of-a-single-early-intravesical-instillation-of-pirarubicin-to-prevent-bladder-recurrence-after-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma-jcog1403-utuc-thp-phase-iii
#4
Kenichi Miyamoto, Akihiro Ito, Masashi Wakabayashi, Junko Eba, Yoichi Arai, Hiroyuki Nishiyama, Mikio Sugimoto, Ryo Yamashita, Yoshiyuki Kakehi
Observation is the current standard for managing cases of Stage 0a-III upper tract urothelial carcinoma after radical nephroureterectomy. A randomized Phase III trial commenced in Japan during October 2016. The trial is designed to investigate the superiority of a single early intravesical instillation of pirarubicin, compared with observation, in terms of relapse-free survival after radical nephroureterectomy for Stage 0a-III upper tract urothelial carcinoma. During a 5-year period, 310 patients will be recruited from 43 Japanese institutions...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29135410/tissue-based-molecular-markers-in-upper-tract-urothelial-carcinoma-and-their-prognostic-implications
#5
Ricardo L Favaretto, Stênio C Zequi, Renato A R Oliveira, Thiago Santana, Walter H Costa, Isabela W Cunha, Gustavo C Guimarães
Upper tract urothelial carcinoma (UTUC) is a rare and aggressive disease that is associated with high rates of recurrence and death. Radical nephroureterectomy (RNU) with excision of the bladder cuff is considered the standard of care for high-risk UTUC, whereas kidney-sparing techniques can be indicated for select patients with low-risk disease. There is a significant lack of clinical and pathological prognostic factors for stratifying patients with regard to making treatment decisions. Incorporation of tissue-based molecular markers into prognostic tools could help accurately stratify patients for clinical decision-making in this heterogeneous disease...
November 17, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29135284/atezolizumab-in-urothelial-bladder-carcinoma
#6
Zineb Hamilou, Pernelle Lavaud, Yohann Loriot
Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy. Recently, immune-checkpoint inhibitors transformed the management and prognosis of many malignancies and will certainly redefine the standard of care for bladder cancer. Atezolizumab, an antiprogrammed cell death ligand-1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016 for patients with urothelial carcinoma...
November 14, 2017: Future Oncology
https://www.readbyqxmd.com/read/29133936/the-rho-gtpase-signalling-pathway-in-urothelial-carcinoma
#7
REVIEW
Solomon L Woldu, Ryan C Hutchinson, Laura-Maria Krabbe, Oner Sanli, Vitaly Margulis
Urothelial carcinoma remains a clinical challenge: non-muscle-invasive disease has a high rate of recurrence and risk of progression, and outcomes for patients with advanced disease are poor, owing to a lack of effective systemic therapies. The Rho GTPase family of enzymes was first identified >30 years ago and contains >20 members, which are divided into eight subfamilies: Cdc42, Rac, Rho, RhoUV, RhoBTB, RhoDF, RhoH, and Rnd. Rho GTPases are molecular on-off switches, which are increasingly being understood to have a critical role in a number of cellular processes, including cell migration, cell polarity, cell adhesion, cell cycle progression, and regulation of the cytoskeleton...
November 14, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29131763/immune-checkpoint-inhibitor-cancer-therapy-spectrum-of-imaging-findings
#8
Gary X Wang, Vikram Kurra, Justin F Gainor, Ryan J Sullivan, Keith T Flaherty, Susanna I Lee, Florian J Fintelmann
Immune checkpoint inhibitors are a new class of cancer therapeutics that have demonstrated striking successes in a rapid series of clinical trials. Consequently, these drugs have dramatically increased in clinical use since being first approved for advanced melanoma in 2011. Current indications in addition to melanoma are non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, and classical Hodgkin lymphoma. A small subset of patients treated with immune checkpoint inhibitors undergoes an atypical treatment response pattern termed pseudoprogression: New or enlarging lesions appear after initiation of therapy, thereby mimicking tumor progression, followed by an eventual decrease in total tumor burden...
November 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29130942/high-grade-urothelial-carcinoma-on-urine-cytology-resembling-umbrella-cells
#9
Andrew A Renshaw, Edwin W Gould
CONTEXT: High-grade urothelial carcinoma (UC) cells have many appearances on urine cytology, but according to The Paris System, they can be easily distinguished from umbrella cells. OBJECTIVE: We aimed to define the incidence and appearance of high-grade UC cells that resemble umbrella cells in Cytospin preparations on urine cytology. RESULTS: Cytospin preparations from 331 cases with biopsy follow-up (230 benign/low-grade and 101 malignant [22 carcinoma in situ, 52 papillary, 19 invasive UC, 8 other] cases) were reviewed...
November 11, 2017: Acta Cytologica
https://www.readbyqxmd.com/read/29126388/yrna-expression-predicts-survival-in-bladder-cancer-patients
#10
Yuri Tolkach, Anna Franziska Stahl, Eva-Maria Niehoff, Chenming Zhao, Glen Kristiansen, Stefan Cajetan Müller, Jörg Ellinger
BACKGROUND: Non-coding RNAs play an important role in human carcinogenesis. YRNAs (Ro-associated Y), a novel class of non-coding RNAs, have been identified as biomarker in various malignancies, but remain to be studied in urinary bladder cancer (BCA) patients. METHODS: The expression of all four YRNAs (RNY1, RNY3, RNY4, RNY5) was determined in archival BCA (urothelial carcinoma, n = 88) and normal urothelial bladder (n = 30) tissues using quantitative real-time PCR...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29125238/lncrna-uca1-promotes-proliferation-and-cisplatin-resistance-of-oral-squamous-cell-carcinoma-by-sunppressing-mir-184-expression
#11
Zheng Fang, Junfang Zhao, Weihong Xie, Qiang Sun, Haibin Wang, Bin Qiao
Chemotherapy resistance has become the main obstacle for the effective treatment of human cancers. Long non-coding RNA urothelial cancer associated 1 (UCA1) is generally regarded as an oncogene in some cancers. However, the function and molecular mechanism of UCA1 implicated in cisplatin (CDDP) chemoresistance of oral squamous cell carcinoma (OSCC) is still not fully established. UCA1 expression in tumor tissues and cells was tested by qRT-PCR. MTT, flow cytometry and caspase-3 activity analysis were explored to evaluate the CDDP sensitivity in OSCC cells...
November 10, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29119638/biphasic-papillary-renal-cell-carcinoma-is-a-rare-morphologic-variant-with-frequent-multifocality-a-study-of-28-cases
#12
Kiril Trpkov, Daniel Athanazio, Cristina Magi-Galluzzi, Helene Yilmaz, David Clouston, Abbas Agaimy, Sean R Williamson, Fadi Brimo, Jose I Lopez, Monika Ulamec, Nathalie Rioux-Leclercq, Maysoun Kassem, Nilesh Gupta, Arndt Hartmann, Xavier Leroy, Samir Al Bashir, Asli Yilmaz, Ondřej Hes
AIMS: To further characterize biphasic squamoid renal cell carcinoma (RCC), a recently proposed variant of papillary RCC. METHODS AND RESULTS: We identified 28 tumors from multiple institutions. They typically demonstrated two cell populations - larger cells with eosinophilic cytoplasm and higher-grade nuclei, surrounded by smaller, amphophilic cells with scanty cytoplasm. The dual morphology was variable (median 72.5% of tumor, range 5-100%); emperipolesis was found in all cases...
November 8, 2017: Histopathology
https://www.readbyqxmd.com/read/29118536/characteristics-of-bladder-neoplasms-in-the-young-population-of-saudi-arabia
#13
Abdulrahman I Alabdulkareem, Fares H Al-Jahdali, Ahmed I Nazers, Sultan S Alkhateeb
Context: Bladder neoplasms are a well-studied subject in medicine. However, the evidence of bladder neoplasms in children and the young adult population (≤40 years), particularly in Saudi Arabia, is lacking. Aims: The aims of this study were to identify histopathological characteristics as well as clinical features, prognosis, and treatment of bladder neoplasms in this age group in a single tertiary referral center, Riyadh, Saudi Arabia. Settings and Design: A retrospective cohort study...
October 2017: Urology Annals
https://www.readbyqxmd.com/read/29115416/annexin-a2-and-cancer-a-systematic-review
#14
Maria V Christensen, Claus K Høgdall, Kirsten M Jochumsen, Estrid V S Høgdall
Annexin A2 is a 36-kDa protein interfering with multiple cellular processes especially in cancer progression. The present review aimed to show the relations between Annexin A2 and cancer. A systematic search for studies investigating cancer and Annexin A2 expression was conducted using PubMed. Acute lymphoblastic leukaemia, acute promyelocytic leukaemia, clear cell renal cell carcinoma, breast, cervical, colorectal, endometrial, gastric cancer, glioblastoma, hepatocellular carcinoma, lung, multiple myeloma, oesophageal squamous cell carcinoma, ovarian cancer, pancreatic duct adenocarcinoma, prostate cancer and urothelial carcinoma were evaluated...
November 8, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29113841/immunotherapy-with-checkpoint-blockade-in-the-treatment-of-urothelial-carcinoma
#15
REVIEW
Arlene O Siefker-Radtke, Andrea B Apolo, Trinity J Bivalacqua, Philippe E Spiess, Peter C Black
PURPOSE: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for non-muscle-invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. MATERIALS AND METHODS: The PubMed database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma...
November 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29113184/lncrna-uca1-promotes-the-invasion-and-emt-of-bladder-cancer-cells-by-regulating-the-mir-143-hmgb1-pathway
#16
Junhua Luo, Jing Chen, Hang Li, Yu Yang, Haichao Yun, Shangqi Yang, Xiangming Mao
The long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) is an oncogenic lncRNA in bladder cancer, and its upregulation is associated with enhanced cell invasion. However, the underlying mechanism remains to be elucidated. The present study demonstrated that UCA1 was positively associated with cell invasion ability and promoted epithelial-mesenchymal transition (EMT) of bladder cancer cells by inducing high mobility group box 1 (HMGB1). Furthermore, bioinformatics and luciferase reporter assays demonstrated binding sites of the tumor suppressive miR-143 within UCA1 and the 3'untranslated region of HMGB1...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29111177/association-of-androgen-receptor-expression-on-tumor-cells-and-pd-l1-expression-in-muscle-invasive-and-metastatic-urothelial-carcinoma-insights-for-clinical-research
#17
Andrea Necchi, Salvatore Lo Vullo, Patrizia Giannatempo, Daniele Raggi, Federica Perrone, Nicola Nicolai, Mario Catanzaro, Davide Biasoni, Tullio Torelli, Luigi Piva, Silvia Stagni, Roberto Salvioni, Luigi Mariani, Maurizio Colecchia
BACKGROUND: Limited information is available regarding the use of androgen receptor (AR) immunohistochemical expression in muscle-invasive or metastatic urothelial carcinoma. We aimed to evaluate the frequency of AR expression by tumor cells (TC), its prognostic role, and its relationship with programmed cell-death ligand 1 (PD-L1) expression in these patients. PATIENTS AND METHODS: From September 2015 to January 2017, we collected tissue from patients who received platinum-based chemotherapy at our center...
October 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29108369/nephroureterectomy-increase-5-year-survival-in-patients-on-dialysis-with-upper-urinary-tract-urothelial-carcinoma
#18
Cih-En Huang, Yao-Hsu Yang, Wen-Cheng Chen, Kuo-Tsai Huang, Pau-Chung Chen, Ying-Huang Tsai, Wei-Yu Lin
Background: There is a high incidence rate of upper tract urothelial carcinoma (UTUC) in patients on dialysis. However, the studies about nephroureterectomy (NU) in this high surgical risk group are limited. The aim of this study is to investigate the outcomes of NU in this population. Results: There were total 931 patients enrolled and 218, 582, 131 patients were non-NU, unilateral and one-stage bilateral NU, respectively. NU provided better 5-year overall survival (66% versus 51% in non-NU, P = 0...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108329/risk-of-acute-myocardial-infarction-in-upper-tract-urothelial-carcinoma-patients-receiving-radical-nephroureterectomy-a-population-based-cohort-study
#19
Shih-Yi Lin, Cheng-Li Lin, Chao-Hsiang Chang, His-Chin Wu, I-Kuan Wang, Che-Yi Chou, Ji-An Liang
Background: The outcomes of upper tract urothelial carcinoma (UTUC) receiving radical nephroureterectomy were usually limited to small sample size, case-control studies, and often focused on cancer progression. Risk of acute myocardial infarction (AMI) in these patients was never investigated. Results: The overall incidences of AMI were 3.39, 1.44, and 1.70 per 10,000 person-years in the radical nephroureterectomy, nonnephroureterectomy, and non-UTUC cohorts, respectively...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29107664/eruption-of-lymphocyte-recovery-with-atypical-lymphocytes-mimicking-a-primary-cutaneous-t-cell-lymphoma-a-series-of-12-patients
#20
Charlotte Hurabielle, Emilie Sbidian, Helmut Beltraminelli, Brigitte Bouchindhomme, Catherine Chassagne-Clément, Brigitte Balme, Céline Bossard, Marie-Hélène Delfau-Larue, Pierre Wolkenstein, Olivier Chosidow, Catherine Cordonnier, Andrea Toma, Cécile Pautas, Nicolas Ortonne
Eruption of lymphocyte recovery (ELR) may occur during bone marrow aplasia after chemotherapies. We reviewed the clinical and pathologic features of 12 patients (male/female: 7/5, median age: 61years) with an atypical ELR histologically mimicking a primary cutaneous T-cell lymphoma (CTCL) such as Sézary Syndrome or CD30+ T-cell lymphoproliferative disorder (LPD). All the patients displayed an erythematous maculopapular eruption on the trunk and the limbs, associated with fever. All but one had received a polychemotherapy for an acute myeloid leukemia (n=10) or an urothelial carcinoma (n=1) before the occurrence of the skin eruption...
October 28, 2017: Human Pathology
keyword
keyword
19765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"